There's some interesting news on the topic of drugs that could be used to treat people with Covid-19. Most, if not all, of the recent candidates have focused on their ability to inhibit replication of the RNA virus geneome. So far, none of them have worked well enough to get beyond preliminary lab studies.
Today I read about what may be a more successful approach. It was already known that proteolysis (enzymes that cut proteins) plays a crucial role in the life cycle of SARS-CoV-2, as it does in most positive-sense RNA viruses. Inhibitors targeting both viral and cellular protease enzymes have previously shown the ability to inhibit SARS-CoV-2 replication in cell culture models. Here the authors at the University of Liverpool (in the UK) and the Institut Pasteur (Paris, France) present the first comprehensive study of proteolysis during SARS-CoV-2 infection, and its implications for antiviral intervention.
Two drugs used to treat cancer, Bafetinib (experimental) and Sorafenib (now approved to treat kidney and liver cancer) inhibited SARS-CoV-2 virus replication, at concentrations that did not result in cytotoxicity (cell death) in a human cell-line model of infection. The methods described in this paper are now being used to look for more drugs with possibly greater anti-viral activity that also can be safely used in patients. Hopefully, at least one of them can be developed to treat people already infected with SARS-CoV-2.
The popular press version is here:
Researchers at the University of Liverpool have shown how SARS-CoV-2 viral proteases attack the host cell, and how this can be targeted to stop virus replication in cell culture using existing drugs.
phys.org
Here is the link to the
Nature paper itself:
During SARS-CoV-2 replication, viral and cellular proteases play crucial roles and have been shown to be promising anti-viral targets. Here, Meyer et al. apply mass spectrometry to characterize the proteolytic cleavage profile of viral and cellular proteins in vitro.
www.nature.com
I always prefer reading the version as it appears in print instead of the online version: